Francesco Forconi
Overview
Explore the profile of Francesco Forconi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
4641
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ondrisova L, Seda V, Hlavac K, Pavelkova P, Hoferkova E, Chiodin G, et al.
J Clin Invest
. 2024 Oct;
134(23).
PMID: 39436708
Bruton tyrosine kinase (BTK) inhibitor therapy induces peripheral blood lymphocytosis in chronic lymphocytic leukemia (CLL), which lasts for several months. It remains unclear whether nongenetic adaptation mechanisms exist, allowing CLL...
2.
Graham L, Fisher J, Doyle A, Sale B, Del Rio L, French A, et al.
Front Oncol
. 2024 Sep;
14:1404051.
PMID: 39286025
Strategies to mobilise natural killer (NK) cells against cancer include tumour-targeting antibodies, NK cell engagers (NKCEs) and the adoptive transfer of expanded healthy donor-derived NK cells. Genetic and functional studies...
3.
4.
Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, et al.
Leukemia
. 2024 Jun;
38(7):1642-1644.
PMID: 38851853
No abstract available.
5.
Kater A, Arslan O, Demirkan F, Herishanu Y, Ferhanoglu B, Diaz M, et al.
Lancet Oncol
. 2024 Mar;
25(4):463-473.
PMID: 38467131
Background: Most patients with chronic lymphocytic leukaemia progress after treatment or retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent treatment options. Response levels to the single-agent venetoclax in...
6.
Munir T, Cairns D, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al.
N Engl J Med
. 2023 Dec;
390(4):326-337.
PMID: 38078508
Background: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment...
7.
Stevenson F, Forconi F
Blood
. 2023 Nov;
143(12):1091-1100.
PMID: 37992212
There are 2 mandatory features added sequentially en route to classical follicular lymphoma (FL): first, the t(14;18) translocation, which upregulates BCL2, and second, the introduction of sequence motifs into the...
8.
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression
Fisher J, Doyle A, Graham L, Sonar S, Sale B, Henderson I, et al.
Leukemia
. 2023 Aug;
37(10):2036-2049.
PMID: 37528310
The first-in-class inhibitor of exportin-1 (XPO1) selinexor is currently under clinical investigation in combination with the BTK inhibitor ibrutinib for patients with chronic lymphocytic leukaemia (CLL) or non-Hodgkin lymphoma. Selinexor...
9.
Forconi F, Ashton-Key M, Meakin N
N Engl J Med
. 2023 May;
388(21):2010-2012.
PMID: 37224205
No abstract available.
10.
Bryant D, Smith L, Rogers-Broadway K, Karydis L, Woo J, Blunt M, et al.
Leukemia
. 2023 May;
37(7):1454-1463.
PMID: 37169950
Chronic lymphocytic leukaemia (CLL) cells can express unmutated (U-CLL) or mutated (M-CLL) immunoglobulin heavy chain (IGHV) genes with differing clinical behaviours, variable B cell receptor (BCR) signalling capacity and distinct...